CLINICAL APPLICATION OF DRIED BLOOD SPOT FOR MONITORING STUDIES OF TAMOXIFEN, ENDOXIFEN, AND 4-HYDROXYTAMOXIFEN IN BREAST CANCER PATIENT USING LIQUID CHROMATOGRAPHY–TANDEM MASS SPECTROMETRY
Objective: To determine tamoxifen (TAM) and its metabolites, endoxifen (END) and 4-hydroxytamoxifen (4-HT) in patients' DBS simultaneously for monitoring studies purposes.
Methods: The UPLC-MS/MS method was developed and validated with clomiphene as the internal standard. Optimization was done by evaluating several parameters that affect the efficiency of DBS preparation and analysis of TAM and its metabolites.
Results: Sample preparation was performed by protein precipitation using methanol. The separation was performed on UPLC Class BEH C18 using formic acid 0.1%-formic acid 0.1% in acetonitrile (35:65) as the mobile phase in isocratic mode at 0.25 ml/minute. The mass detection was performed on Waters Xevo TQD using ESI+for TAM, END, 4-HT, and clomiphene as internal standard with m/z value: 372.2>72.27; 374.29>58.2; 388.29>72.19; dan 406.28>100.17 respectively. This method was linear within the range of 5-200 ng/ml for TAM; 1-40 ng/ml for END; and 0.5-20 ng/ml for 4-HT with r value of ≥0.9983; ≥0.9964; and ≥0.9981. %diff and %CV of the assay were within 15% and within 20% for LLOQ. The method was applied to 29 breast cancer patients, where the results lied between 30.29 and 188.63 ng/ml for tamoxifen, 1.45 and 28.77 ng/ml for endoxifen, 0.21 and 11.28 ng/ml for 4-hydroxytamoxifen.
Conclusion: This method has successfully fulfilled validation requirement referring to 2011 EMA and 2013 FDA guidelines. The method was successfully applied to determine TAM, END, and 4-HT in DBS of breast cancer ER+patients. TAM and its metabolites level in patients were showed high variability with END concentration of 2 patients below the clinical threshold.
2. Goodman LS, Brunton LL, Chabner B, Knollmann BC. Goodman and gilman's pharmacological basis of therapeutics. New York: McGraw-Hill; 2012.
3. Jager NGL, Rosing H, Schellens JHM, Beijnen JH, Linn SC. Use of dried blood spots for the determination of serum concentrations of TAM and END. Breast Cancer Res Treat 2014;146:137–44.
4. Madlensky L, Natarajan L, Tchu S, Pu M, Mortimer J, Flatt S, et al. TAM metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes. Clin Pharmacol Ther 2010;89:718-25.
5. Antunes M, Raymundo S, de Oliveira, Staudt D, Gössling G, Peteffi G, et al. Ultra-high performance liquid chromatography tandem mass spectrometric method for the determination of TAM, N-desmethyl TAM, 4-HT and END in dried blood spots-development, validation and clinical application during breast cancer adjuvant therapy. Talanta 2014;132:775-84.
6. Li W, Tse FLS. Dried blood spot sampling in combination with LC-MS/MS for quantitative analysis of small molecules. Biomed Chromatogr 2010;24:49–65.
7. Tre-Hardy M, Capron A, Antunes M, Linden R, Wallemacq P. Fast method for simultaneous quantification of TAM and metabolites in dried blood spots using an entry level LC–MS/MS system. Clin Biochem 2016;49:1295-8.
8. Jager N, Rosing H, Linn S, Schellens J, Beijnen J. Importance of highly selective LC–MS/MS analysis for the accurate quantification of TAM and its metabolites: focus on END and 4-HT. Breast Cancer Res Treat 2012;133:793-8.
9. European Medicines Agency. Guideline of Bioanalytical Method Validation. Sciences Medicines Health. London: European Medicines Agency; 2011.
10. Food and Drug Administration. Guidance for Industry, Bioanalytical Method Validation. U. S. Department of Health and Human Services; 2013.
11. Hemavathi G, Hipparagi SM. Sensitive LC-MS/MS method for the simultaneous determination of bisoprolol and triamterene in human plasma. Asian J Pharm Clin Res 2017;10:341.
12. Mukti AA, Jannah F, Nurrochmad A, Lukitaningsih E. Development and validation method for quantitative determination of ciprofloxacin in human plasma and its application in bioequivalence test. Asian J Pharm Clin Res 2016;9:89–95.
13. Saladores P, Mürdter T, Eccles D, Chowbay B, Zgheib NK, Winter S, et al. Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer. Pharmacogenomics J 2015;15:84–94.